In 75 melanoma patients with a total of 566 brain metastases, given a median of 20 Gy SRS and anti‐PD‐1/anti‐CTLA‐4, concurrent immunotherapy and SRS led to a greater median per cent reduction in lesion volume than non‐concurrent therapy.121. Here, CTLA4 is linked to melanoma.